Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Provexis plc (PXS.L)
Reading, GB
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot formation, which is linked to severe cardiovascular conditions such as heart attacks and strokes. This versatile extract is available in syrup and powder formats for integration into various food and beverage items, as well as dietary supplements. The company also provides Fruitflow + Omega-3, a capsule-based supplement aimed at fostering healthy blood circulation and supporting normal cardiac function. Provexis plc holds a strategic collaboration agreement with By-Health Co., Ltd. Its products are distributed through both physical retail channels and digital online platforms. Founded in 1999, Provexis plc has its headquarters situated in Reading, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +8.81% | +2.94% | -27.08% | +68.00% | +16.67% | +110.63% | +61.54% | +23.09% | +275.00% | -43.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+61.1% ★ Q3'25: -6.0% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+33.3% ★ Q3'25: +200.0% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-42.0% Q3'25: -98.0% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-34.8% Q3'25: -84.3% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-806.8% Q3'25: -1,403.5% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.0% Q3'25: +5.8% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q3'25: 0.00× (vs Q3'23)
| Metric |
Mar 2006 actual |
Mar 2007 actual |
Mar 2008 actual |
Mar 2009 actual |
Mar 2010 actual |
|---|---|---|---|---|---|
| Revenue |
268.0K
est: 294.4K (-9.0%)
|
67.0K
est: 984.5K (-93.2%)
|
162.0K
est: 1.04M (-84.4%)
|
5.0K
est: 2.26M (-99.8%)
|
15.0K
est: 4.96M (-99.7%)
|
| EBITDA |
-3.09M
est: -64.8K (-4,671.9%)
|
-1.46M
est: -9.77M (+85.1%)
|
-1.14M
est: -2.63M (+56.8%)
|
-4.59M
est: -2.69M (-70.7%)
|
-1.77M
est: -9.99M (+82.3%)
|
| EBIT |
-3.47M
est: -207.2K (-1,576.0%)
|
-1.46M
est: -11.67M (+87.5%)
|
-1.15M
est: -3.03M (+62.0%)
|
-4.61M
est: -2.62M (-75.8%)
|
-1.79M
est: -10.30M (+82.6%)
|
| Net Income |
-49.0K
est: -28.57M (+99.8%)
|
-2.44M
est: -11.41M (+78.6%)
|
-1.19M
est: -3.09M (+61.5%)
|
-4.57M
est: -2.58M (-77.2%)
|
-1.65M
est: -10.06M (+83.6%)
|
| SGA |
2.98M
est: 226.1K (+1,216.8%)
|
1.23M
est: 756.2K (+62.9%)
|
911.0K
est: 799.1K (+14.0%)
|
847.0K
est: 2.15M (-60.5%)
|
1.06M
est: 2.13M (-50.3%)
|
| EPS |
0.00
est: -0.01 (+98.4%)
|
-0.01
est: -0.01 (+24.2%)
|
0.00
est: 0.00 (-54.7%)
|
-0.01
est: 0.00 (-542.1%)
|
0.00
est: 0.00 (-177.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian Ford | Chief Executive Officer, Chief Financial Officer, Company Secretary & Executive Director | 185.6K | male |
| Niamh Ann O'Kennedy | Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director | 39.7K | — |
| Asim K. Duttaroy FICN | Consultant & Member of Scientific Advisory Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PXS.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
